论文部分内容阅读
[目的]评价中药艾迪注射液联合三氧化二砷(As2O3)行肝动脉插管化疗栓塞(TACE)在原发性肝癌(HCC)患者中的临床治疗效果。[方法]将80例HCC患者随机分为2组各40例,均接受超选择性TACE术。治疗组给予艾迪注射液100 ml加0.9%氯化钠500 ml静脉滴注(静滴),d1~d21;静滴同时进行肝动脉介入治疗,药物为As2O3注射液10 mg;对照组采用常规化疗药物(5-氟尿嘧啶1 000 mg,顺铂50~70 mg,阿霉素40~50 mg,丝裂霉素8~16 mg),经导管向供血动脉内注入碘油-化疗药物乳化剂,随后用明胶海绵(GS)或聚乙烯醇(PVA)微球栓塞该动脉。2组均4周为1个疗程,共治疗4个疗程。[结果]治疗组40例中,完全缓解(CR)10例,部分缓解(PR)18例,无变化(SD)8例,恶化(PD)2例,死亡2例,总有效率为70.0%,甲胎蛋白(AFP)下降率为80.0%,肿瘤缩小率为77.5%,中位生存期为15个月。对照组40例中,CR 6例,PR 10例,SD 10例,PD 10例,死亡4例,总有效率为40.0%,AFP下降率为37.5%,肿瘤缩小率为55.0%,中位生存期为8.5个月。2组中度以上不良反应率分别为7.5%和35.0%。[结论]艾迪注射液联合As2O3行TACE是一种安全、有效的治疗HCC的方法。
[Objective] To evaluate the clinical effect of traditional Chinese medicine Aidi injection combined with arsenic trioxide (As2O3) on hepatic arterial chemoembolization (TACE) in patients with primary liver cancer (HCC). [Methods] Eighty patients with HCC were randomly divided into two groups of 40 cases, all underwent superselective TACE. The treatment group was given Aidi Injection 100 ml plus 0.9% sodium chloride 500 ml intravenous infusion (intravenous drip), d1 ~ d21; intravenous infusion of hepatic artery intervention, drug As2O3 injection 10 mg; control group using conventional Chemotherapy drugs (5-fluorouracil 1000 mg, cisplatin 50-70 mg, doxorubicin 40-50 mg, mitomycin 8-16 mg) were injected into the feeding artery through the catheter lipiodol-chemotherapeutic emulsifier, The artery is then embolized with gelatin sponge (GS) or polyvinyl alcohol (PVA) microspheres. 2 groups were 4 weeks for a course of treatment, a total of 4 courses of treatment. [Results] Among the 40 patients in the treatment group, 10 were completely relieved (CR), 18 were partly relieved (PR), 8 were unchanged (SD), 2 were malignant (PD) and 2 died. The total effective rate was 70.0% , AFP decreased 80.0%, tumor shrinkage rate was 77.5%, median survival was 15 months. The control group of 40 cases, CR 6 cases, PR 10 cases, SD 10 cases, PD 10 cases, 4 patients died, the total effective rate was 40.0%, AFP decreased rate of 37.5%, tumor shrinkage rate was 55.0%, median survival The period is 8.5 months. Two groups of moderate and more adverse reactions were 7.5% and 35.0%. [Conclusion] Aidi injection combined with As2O3 in TACE is a safe and effective method for the treatment of HCC.